Education
About Us
Working with TipRanks
Follow Us
DRI Healthcare (TSE:DHT.UN)
TSX:DHT.UN
Earnings Data
Report Date
May 11, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.81Last Year’s EPS
0.6Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a predominately positive operational and financial story: record margins and adjusted EBITDA, cash receipt growth, successful capital allocation actions (unit buybacks, preferred redemptions, and longer-dated private placement debt), and outperformance from several recently acquired assets (Orserdu, Ekterly, Xempozyme). The company also outlined a funded growth plan through 2030 and a proprietary risk framework and AI integration to scale deal evaluation. Offsetting these positives are notable asset-specific headwinds (notably Omidria impairment, Vonjo and legacy product pressures), some lumpiness from one-time items, and a deliberate shift toward more pre‑approval deals that may slow near-term deployment pace. Overall, the highlights materially outweigh the lowlights, with management framing challenges clearly and taking actions to strengthen the balance sheet and underwriting process.Company Guidance
Record Financial Performance and Margin Expansion
Total income of $198.6M for FY2025, up 6% year-over-year; normalized trailing 12-month adjusted EBITDA margin of 84% and normalized annual adjusted EBITDA margin of 88% (highest in company history); Q4 2025 adjusted EBITDA margin of 91% vs 83% in Q4 2024; trailing 12-month adjusted EBITDA of $165M.
Cash Receipts Growth
Normalized total cash receipts of $196.4M for the 12 months ending Dec 31, 2025, a $6.5M (3.4%) increase versus 2024; Q4 cash receipts up 14% quarter-over-quarter drivers cited in prepared remarks.
Exceeded 5-Year Deployment Target
Exceeded the 5-year deployment goal of $1.25B through upfront and committed capital deployments including the Viridian and Ekterly transactions, demonstrating strong origination and structuring capability.
Strong Performance from Key Assets (Orserdu, Ekterly, Xempozyme, Xolair, Casgevy)
Orserdu Q4 royalty receipts of $19M, a 38% YoY increase vs Q4 2024; Orserdu triggered a $5M milestone and Q1'26 receipts anticipated at ~$27M (≈$22M royalties + $5M milestone). Ekterly showed early traction with first receipts in 2025 and implied annual run rate >$140M from Q4 sales; Xempozyme Q4 receipts $2.5M with Sanofi reporting $71M Q4 and >$250M FY sales; Casgevy Q4 sales $54M and DRI to record a $5M license fee in Q1 2026; Xolair growth following food allergy launch.
Capital Allocation Actions and Unitholder Returns
Returned in excess of $36M to unitholders via unit repurchases and dividends in 2025; repurchased and canceled ~1.4M units in 2025 (reducing unit count by nearly 3%); aggregate repurchases of 4.6M units at an average price of $7.08 totaling $32.7M; increased quarterly distribution from $0.10 to $0.11 per unit (10% increase) beginning Q1 2026.
Balance Sheet and Financing Improvements
Redeemed/cancelled preferred shares ($10M face value for $9.5M and subsequent $9.9M for $9.8M plus accrued interest); negotiated swaps of majority remaining preferred into converts to reduce coupon and extend maturities; priced private placement debt to term out portion of bank facility to 5- and 7-year maturities; $239M of credit availability and $42.4M cash on hand as of Dec 31, 2025.
Operational Enhancements and Risk Framework
Completed internalization of the manager producing meaningful cost synergies and higher margins; established a proprietary data-driven risk assessment framework to guide deal selection, sizing and pricing; integrated AI into workflows with dedicated team members and internal compute to improve execution speed and quality.
Long-term Growth Targets and Funding Plan
2025 royalty income of $188.7M exceeded stated target range of $172M–$182M; management tracking a 12% royalty income CAGR off 2022 base (above prior high-single-digit target); plans to invest $800M–$1B from 2026–2030 (fully funded by current capital structure) with aspiration for low-teens adjusted EBITDA CAGR to 2030.
TSE:DHT.UN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TSE:DHT.UN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 03, 2026 | C$16.77 | C$16.35 | -2.50% |
Nov 05, 2025 | C$15.45 | C$15.25 | -1.29% |
Aug 13, 2025 | C$14.81 | C$14.12 | -4.69% |
May 12, 2025 | C$12.16 | C$12.20 | +0.33% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does DRI Healthcare (TSE:DHT.UN) report earnings?
DRI Healthcare (TSE:DHT.UN) is schdueled to report earning on May 11, 2026, Before Open (Confirmed).
What is DRI Healthcare (TSE:DHT.UN) earnings time?
DRI Healthcare (TSE:DHT.UN) earnings time is at May 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:DHT.UN EPS forecast?
TSE:DHT.UN EPS forecast for the fiscal quarter 2026 (Q1) is 0.81.